|
Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease Clinical research trials and Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease. Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease clinical trial. Human subjects often get the best healthcare possible for their Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease  Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease
Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease
For Condition: Coronary Disease,Cardiovascular Diseases,Heart Diseases,Coronary Arteriosclerosis
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine the relative risk in a defined population of angiographically demonstrated coronary artery disease due to genetic polymorphisms at the four apolipoprotein genomic regions.
Details: BACKGROUND: Numerous epidemiological studies have shown that the risk of coronary heart disease is strongly influenced by plasma lipid levels, especially HDL and LDL cholesterol, and their specific apolipoprotein constituents. Genetic studies have established significant heritability of these lipid components, and have also identified relatively rare major genes that result in extreme lipid values and increased risk of coronary heart disease. Geneticists have identified a number of segregating polymorphisms at the four major apolipoprotein genomic regions, using a combination of protein and DNA assays. However, in 1988 when the study was initiated, the relationship between these polymorphisms and risk of coronary heart disease had not yet been properly defined. DESIGN NARRATIVE: The study had a case-control design. Cases were consecutively selected from the pool of eligible Latter Day Saints Hospital patients referred for coronary angiogram. Eligibility criteria included residing in the Wasatch County or Southern Idaho counties, being healthy at the time of angiogram and having greater than 60 percent occlusion. Approximately 80-100 controls were retrospectively selected from the clinic records of the past four years. Fasting lipid profiles were defined for cases and controls in terms of total cholesterol, total triglycerides, HDL levels, LDL levels, VLDL levels, density gradient distribution of HDL-LDL subfractions, and levels of apo A-1, apo B, and apo E. The distribution of genetic polymorphisms at the four major apolipoprotein genomic regions was determined by typing all cases and controls for isoforms of apo E and apo AIV and a wide variety of DNA polymorphisms. Approximately 800 first degree relatives of cases and controls were also typed for DNA polymorphisms. Data were collected on risk factors including smoking, alcohol use, obesity, physical activity, and diet. Clinical data included medical and family history of cardiovascular disease and medication status. Multivariate statistical analysis was used to define the relative risk of coronary disease associated with segregating polymorphisms, and DNA haplotypes at these loci in conjunction with lipid profiles and risk factors. Analyses were also conducted on the extent to which the genetic segregation at these apolipoprotein genomic regions influenced the distribution of lipid profiles and whether the distribution of risk factors was influenced by the interaction of environmental risk factors such as smoking and genotypes at these regions.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 1104;
Study Start Date: April 1988
Record last reviewed: May 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005225
Other Coronary Arteriosclerosis Studies:
1. Physical Activity and Cardiovascular Risk in Black Girls
2. The safety and efficacy of adjunct carvedilol in children with moderate heart failure
3. Evaluation of Low Literacy CVD Nutrition Education
4. Multicenter Study of Silent Myocardial Ischemia (MSSMI)
5. Epidemiology of Coronary Calcification in the Elderly
Related Studies:
Other Coronary Arteriosclerosis Clinical Trials
Other Clinical Trials
Other Clinical Trials
Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease
|
|
|
|
|
|
|
|
